Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857 | 0.76 | IDO1 (0.39) | DPP4F2ADRA2ALMNACYP1A2 | |
| SCHEMBL114840 | 0.73 | DPP4 (0.50) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL16970750 | 0.73 | HCAR2 (0.43) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL7454768 | 0.73 | TSHR (0.44) | DPP4F2LMNAALDH1A1CYP1A2 | |
| SCHEMBL119992 | 0.73 | TSHR (0.44) | DPP4F2LMNAALDH1A1CYP1A2 | |
| SCHEMBL96935 | 0.73 | HCAR2 (0.43) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL2657967 | 0.73 | CYP2D6 (0.34) | DPP4F2LMNAALDH1A1CYP1A2 | |
| SCHEMBL16970628 | 0.73 | HCAR2 (0.43) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL131810 | 0.73 | CES2 (0.41) | DPP4F2LMNAALDH1A1CYP1A2 | |
| SCHEMBL3936005 | 0.73 | LMNA (0.43) | ADRA2AADRA2CLMNAHIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 940 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133763-A2 | ALPP-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LIMITED (GB) | 2024-06-27 | — | — | WO | claimed |
| US-20240082409-A1 | Modified peptide ligands for stable delivery of highly potent payloads to tumors: Method of making and using same | LAMHARZI NAJIB (US) | 2024-03-14 | — | — | US | claimed |
| WO-2024054821-A2 | TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND USES THEREOF | EXELIXIS, INC. (US) | 2024-03-14 | — | — | WO | claimed |
| WO-2024028258-A1 | CONJUGATES OF PSMA-BINDING MOIETIES WITH CYTOTOXIC AGENTS | PHILOCHEM AG (CH) | 2024-02-08 | — | — | WO | claimed |
| EP-4274583-A2 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| EP-4262878-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2023-10-25 | — | — | EP | claimed |
| EP-4262987-A1 | ROR1-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | Almac Discovery Limited (GB) | 2023-10-25 | — | — | EP | claimed |
| EP-4237012-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | Avacta Life Sciences Limited (GB) | 2023-09-06 | — | — | EP | claimed |
| WO-2022150555-A2 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022133288-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2022-06-23 | — | — | WO | claimed |
| EP-1223959-B1 | INHIBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | US GOV HEALTH & HUMAN SERV (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2007002222-A2 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2007-01-04 | — | — | WO | claimed |
| US-7132392-B1 | Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-11-07 | — | — | US | claimed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| CN-1511044-A | Elogated and multiple spacers in activatible prodrugs | — | 2004-07-07 | — | — | CN | claimed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | claimed |
| EP-1223959-A2 | INHBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-07-24 | — | — | EP | claimed |
| EP-1163262-A1 | PHENYLALANINE DERIVATIVES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2001028577-A2 | INHIBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-04-26 | — | — | WO | claimed |
| WO-2000056760-A1 | PHENYLALANINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-09-28 | — | — | WO | claimed |